Iluvien alone, based on Alimera's 2017 estimate, is around 400Mill. That would be Europe alone. If we could use those numbers, and use the 14% of net sales forwarded to PSDV(at no costs to us), then we are talking 56 million in revenues in Europe alone. Not to mention potential for US approval of Iluvien for chronic DME and/or Uveitis insert approval. For those who have owned stock in PSDV through the years, the waiting is just about over. As Len Zehr wrote in a SA article years back "we are on the cusp" of a breakthrough. Should be an interest ing balance of 2013. GLTA
Plenty of speculation as to the pop in PPS going on by newbies, shorts and of course us longs. I view Ashton's presentation last week as a major confidence booster in this little gem. Have to believe we are no longer flying under the radar and the smart money is jumping on board. Glad to see all the freaks coming out- usually a sign of good things about to happen. If I were to take a guess as to the catalyst for today's movement I would have to think it is Illuvien related. Even though Ashton has indicated in previous conference calls that PSDV is a takeover target- I seriously doubt that is going to happen at this time. Just happy to see a nice pop with more to come. Good luck buddy.
In the last investors conference at the Waldorf, Paul Aston (CEO) stated that the proceeds from Iluvien sales due pSivida would be approximately 14% to 15% of gross sales. Listen to the web cast, it is still available via PSDV's website. i was equally surprised by those numbers.